Helicobacter pylori infection
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years, regardless of gender; 2. Identified as Hp-positive by 13C/14C-urea breath test; 3.Judged by researchers to require Hp eradication therapy, and the 14-day quadruple bismuth-containing regimen (proton pump inhibitor/P-CAB + bismuth + antibiotic combination) or high-dose dual therapy is selected; 4.(No previous Hp eradication therapy; 5. Willing to receive Hp eradication therapy and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Complicated with severe primary diseases in the hematological, renal, respiratory, digestive, nervous systems or other systems that significantly affect life expectancy; complicated with malignant tumors, mental illnesses, or immunodeficiency diseases expectancy; 2.(2) Having taken oral antibiotics or steroid hormones within 4 weeks before enrollment, or oral acid suppressants within 2 weeks before enrollment; 3.(3) Having taken, or planning to take, other probiotic preparations or yogurt (other than the study drug) within 1 week before enrollment or during the study period; 4.(4) Pregnant or lactating women; 5.(5) Those allergic to probiotics; 6.(6) Patients deemed unsuitable for inclusion in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of digestive tract adverse reactions related to Hp eradication therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hp eradication rate;Duration of total adverse reactions and each individual adverse reaction;Incidence rate of each individual adverse reaction;Incidence rate of adverse reactions;Medication compliance;Changes in SF-6D scale and EQ-5D scores of quality of life scales compared with baseline;Severity of each individual adverse reaction; | — |
Countries
China
Contacts
Shenzhen Hospital of Southern Medical Unversity